NASDAQ: JBIO · Life Sciences · 4 alerts · CIK 1798749
Share price
$15.34Close, Nov 16
Market cap
$1.06B
Shares outstanding
69.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Jade Biosciences, Inc. filings on SEC EDGAR ↗
Jade Biosciences is advancing its pipeline with Jade 301 for Dermatomyositis, leveraging preclinical data showing 2.5-fold higher affinity and 8-fold greater potency than competitor Dazookibart, with a cash runway extending into Q4 2028.
Jade Biosciences reported a net loss of $131.2 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through a June 2026 financing and ATM offerings, ending the period with $475.7 million in cash, cash equivalents, and investments.
Jade Biosciences reported third quarter 2026 financial results, highlighting a cash position of $476 million which is expected to fund operations into Q4 2028. The company is preparing to initiate its Phase 3 EVERGREEN trial for JADE101 in IgA nephropathy ahead of schedule in Q4 2026.
Term
Q3 2026
“The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones. We are preparing to initiate the Phase 3 EVERGREEN trial of JADE101 ahead of schedule, reflecting both our rapid execution and our continued conviction in JADE101’s potential best-in-class profile.”